What is Fate Therapeutics, Inc.'s Market Cap?

Fate Therapeutics, Inc.'s Market Cap is $252.8M, based on as-reported figures from SEC (XBRL) filings.

What is Fate Therapeutics, Inc.'s Enterprise Value?

Fate Therapeutics, Inc.'s Enterprise Value is $99.1M, based on as-reported figures from SEC (XBRL) filings.

What is Fate Therapeutics, Inc.'s Price / Sales?

Fate Therapeutics, Inc.'s Price / Sales is 38.9×, based on as-reported figures from SEC (XBRL) filings.

What is Fate Therapeutics, Inc.'s EV / Revenue?

Fate Therapeutics, Inc.'s EV / Revenue is 15.3×, based on as-reported figures from SEC (XBRL) filings.

What is Fate Therapeutics, Inc.'s EV / EBITDA?

Fate Therapeutics, Inc.'s EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.

What is Fate Therapeutics, Inc.'s Revenue (TTM)?

Fate Therapeutics, Inc.'s Revenue (TTM) is $6.5M, based on as-reported figures from SEC (XBRL) filings.

What is Fate Therapeutics, Inc.'s Net Income (TTM)?

Fate Therapeutics, Inc.'s Net Income (TTM) is -$126.0M, based on as-reported figures from SEC (XBRL) filings.

What is Fate Therapeutics, Inc.'s EBITDA?

Fate Therapeutics, Inc.'s EBITDA is -$121.6M, based on as-reported figures from SEC (XBRL) filings.

What is Fate Therapeutics, Inc.'s Diluted EPS (TTM)?

Fate Therapeutics, Inc.'s Diluted EPS (TTM) is -1.05, based on as-reported figures from SEC (XBRL) filings.

What is Fate Therapeutics, Inc.'s EBITDA Margin?

Fate Therapeutics, Inc.'s EBITDA Margin is -1873.4%, based on as-reported figures from SEC (XBRL) filings.

AKYLA/ Financials

Equity / BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Fate Therapeutics, Inc.

XNAS · usd

SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

FIGI BBG001T888S2

2.11▲ 0.02 (0.96%)

As of 2026-10-23

Price / Volume

Valuation

Market Cap
Enterprise Value
Trailing P/E: —
Price / Sales
EV / Revenue
EV / EBITDA

Financial Highlights

Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt

Trading Information

Previous Close: 2.09
Day's Range: 2.02 – 2.14
52-Week Range: 0.95 – 3.23
Volume: 1.1M
Avg Volume: 1.5M

Share Statistics

Shares Outstanding
Employees: 161
Exchange: XNAS
Listed: 2013-10-01

Share count as of August 6, 2026

Fate Therapeutics, Inc. (FATE) Financial Statements

View

Income Statement

Detail

Standard

Period

Quarterly

Loading Income Statement…

Key questions about Fate Therapeutics, Inc. (FATE)

What is Fate Therapeutics, Inc.'s Market Cap?: Fate Therapeutics, Inc.'s Market Cap is $252.8M, based on as-reported figures from SEC (XBRL) filings.
What is Fate Therapeutics, Inc.'s Enterprise Value?: Fate Therapeutics, Inc.'s Enterprise Value is $99.1M, based on as-reported figures from SEC (XBRL) filings.
What is Fate Therapeutics, Inc.'s Price / Sales?: Fate Therapeutics, Inc.'s Price / Sales is 38.9×, based on as-reported figures from SEC (XBRL) filings.
What is Fate Therapeutics, Inc.'s EV / Revenue?: Fate Therapeutics, Inc.'s EV / Revenue is 15.3×, based on as-reported figures from SEC (XBRL) filings.
What is Fate Therapeutics, Inc.'s EV / EBITDA?: Fate Therapeutics, Inc.'s EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Fate Therapeutics, Inc.'s Revenue (TTM)?: Fate Therapeutics, Inc.'s Revenue (TTM) is $6.5M, based on as-reported figures from SEC (XBRL) filings.
What is Fate Therapeutics, Inc.'s Net Income (TTM)?: Fate Therapeutics, Inc.'s Net Income (TTM) is -$126.0M, based on as-reported figures from SEC (XBRL) filings.
What is Fate Therapeutics, Inc.'s EBITDA?: Fate Therapeutics, Inc.'s EBITDA is -$121.6M, based on as-reported figures from SEC (XBRL) filings.
What is Fate Therapeutics, Inc.'s Diluted EPS (TTM)?: Fate Therapeutics, Inc.'s Diluted EPS (TTM) is -1.05, based on as-reported figures from SEC (XBRL) filings.
What is Fate Therapeutics, Inc.'s EBITDA Margin?: Fate Therapeutics, Inc.'s EBITDA Margin is -1873.4%, based on as-reported figures from SEC (XBRL) filings.

Akyla / Financials · FATEAs-filed SEC (XBRL) data